

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application Number	:	(unassigned)	Confirmation No.
Applicant	:	Andreas Bergmann et al.	
Filed	:	March 25, 2004	
Tech Cntr/AU	:	(unknown)	
Examiner	:	(unknown)	
Entitled	:	Method and Substances for Diagnosis and Therapy of Sepsis and Sepsis-Like Systemic Infections	
Attorney Reference	:	011377-0308769	
Customer Number	:	00909	

MAIL STOP PATENT APPLICATION

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 CFR 1.56, the attention of the U.S. Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. The references cited herein were cited for consideration in the parent application, and, pursuant to 37 CFR 1.98(d), copies of the cited references can be found in the file of the parent application (*U.S. Serial No. 09/806,437, filed May 29, 2001*).

This Information Disclosure Statement is being filed (a) within three months of the U.S. filing date of this non-CPA application, AND (b) before the mailing date of the first Office Action on the merits in the present application. No certification or fee is required.

It is respectfully requested that this information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The Examiner is further respectfully requested to return of a copy of the enclosed Form PTO-1449 with the Examiner's initials in the left column.

The examination and allowance of this Application is respectfully requested.

Respectfully Submitted,

PILLSBURY WINTHROP LLP

By:



Paul L. Sharer
Registration Number 36,004

P.O. Box 10500
McLean, VA 22102
(703) 905-2000 Telephone
(703) 905-2500 Facsimile
Date: March 25, 2004

FORM PTO-1449 (modified)
 To: U.S. Department of Commerce
 (PW FORM PAT-1449)
 Patent and Trademark Office

Atty. Dkt. No.	M#	Client Ref.
	0308769	
Applicant: Andreas BERGMANN et al.		
Appln. No.: unassigned		
Filing Date: March 25, 2004		
Examiner:	Group Art Unit: unassigned	

Date: March 25, 2004

Page **1** of **4**

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
AR						
BR						

FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name		English Abstract	Translation Readily Available		
						Enclosed	No	Enclose	No
CR	42 27 454	02/1994	GERMANY						
DR									
ER									
FR									

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

GR	OKAHARA S ET AL: "SERUM PRO-GASTRIN-RELEASING PEPTIDE (PROGRP) IN SUBJECTS WITH OR WITHOUT HERICOBACTER PYLORIINFECTION" GASTROENTEROLOGY, US, ELSEVIER, NEW YORK, NY., vol. 110, no. 4, April 1996, page A217 XP000884904, ISSN: 0016-5085, abstract		
HR	NORIHARU SHIJUBO ET AL: "ELEVATED PROGASTRIN-RELEASING PEPTIDE (31-98) CONCENTRATIONS IN PLEURAL EFFUSIONS FUE TO SMALL-CELL LUNG CARCINOMA" RESPIRATION, CH, KARGER, BASEL, vol. 63, no. 2, 1 March 1996, pages 106-110 XP000608937, ISSN: 0025-7931, page 107, column 1, paragraphs 2,4, page 107, column 2, paragraph 4; figure 1, page 109, column 2, paragraphs 2,3,		
IR	MIYAKE, Y. ET AL, : "Pro-gastrin-Releasing Peptide (31-98 is a Specific tumor Marker in Patients with Small Cell Lung Carcinoma" CANCER RESEARCH, vol. 54, 15 April 1994, pages 2136 - 2140, XP002132024, page 2137, column 1, line 1 - line 7; figure 2		
JR	GUO Y ET AL.; "PRODUCTION OF ENDOTHELINS BY THE VENTILATORY MUSCLES IN SPETIC SHOCK" AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, US, AMERICAN LUNG ASSOCIATION, NEW YOEK, NY,vol. 1, no. 3, September 1998, pages470-476, XP000879419 ISSN : 1044-1549, page 472, column 2, paragraph 3		
KR	MCLOUGHLIN L ET AL : "CARACTERIZATION OF CIRCULATING PRO-OPIOMELANOCORTIN-RELATED PEPTIDES IN HUMAN SEPTIC SHOCK" JOURNAL OF ENDOCRINOLOGY, GB, BRISTOL, vol. 119, no. 1, October 1988, pages 159-165, XP000879345 ISSN: 0022-0795 cited in the application, abstract, page 161, column 1, paragraph 2		
LR	NYLEN E S ET AL: "PNEUMONITIS-ASSOCIATED HYPERPROCALCITONINEMIA" AMERICAN JOURNAL OF MEDICAL SCIENCES, XX, XX, vol.312, no. 1, July 1996, pages 12-18, XP000879269 ISSN: 0002-9629, page 15, column 1, line 2 - line 5, page 15, column 2, line 5 - line 9		

Examiner _____ Date Considered: _____

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified)
 To: U.S. Department of Commerce
 (PW FORM PAT-1449)
 Patent and Trademark Office

Atty. Dkt. No.	M#	Client Ref.
	0308769	

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Date: March 25, 2004

Page **2** of **4**

Applicant: Andreas BERGMANN et al.

Appln. No.: unassigned

Filing Date: March 25, 2004

Examiner:

Group Art Unit: unassigned

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)

FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name		English Abstract	Translation Readily Available
						Enclosed	No

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

	ASSICOT M ET AL : "HIGH SERUM PROCALCITONIN CONCENTRATIONS IN PATIENTS WITH SEPSIS AND INFECTIONS" LANCET THE, GB, LANCET LIMITED, LONDON, vol. 341, no.8844, 27 February 1993, pages 515-518, XP000371780 ISSN: 0140-6736, abstract		
	KARZAI W ET AL : "PROCALCITONIN-A NEW INDICATOR OF THE SYSTEMIC RESPONSE TO SEVERE INFECTIONS" INFECTION, DE, MMV MEDIZIN VERLAG, MUENCHEN, vol. 25, no. 6, November 1997, pages 329-334, XP000879253 ISSN: 0300-8126, page 329, column 2, paragraph 2		
	QURESHI, N.U. ET AL : "Endogenous neuropeptide Y mediates vasoconstriction during endotoxic and hemorrhagic shock" REGULATORY PEPTIDES, vol. 75-76, 25 September 1998, pages215-220, XP000925467 abstract, page 215, column1 – column 2, line 3, page 219, column 1, paragraph 3		
	NORLANDER, T. ET AL : "Effects of experimental Mycoplasma pulmonis infection on sensory neuropeptides and airway mucosa in the rat" EUROPEAN RESPIRATORY JOURNAL, vol. 10, 1997, pages 2334-2342, XP000925422, abstract, page 2341, column 1, paragraph 2		
	KULLERTZ, G. : "Die Bedeutung der Aktivitätsbestimmung des Enzyms Dipeptidyl-Peptidase IV (DP IV) im klinischen Laboratorium" LAB, MED., vol. 12, 1988, pages 123-130, XP000933866, page 123, column 1- page 124, column 1, paragraph 1, page 125, column 1, paragraph 2 – paragraph 3, table 4, page 128, column 1, paragraph 2, page 129, column 1, paragraph 4 –paragraph 5		
	VANHAM, G. ET AL : "Decreased Expression of the Memory Marker CD26 on Both CD4 + and CD8 + T Lymphocytes of HIV-Infected Subjects" JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, vol. 6, no. 7, July 1993, pages 749-757, XP000925435, page 751, column 1, paragraph 6, page 753, column 2, paragraph 3, page 756, column 1, paragraph 2.		

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified) To: U.S. Department of Commerce (PW FORM PAT-1449) Patent and Trademark Office				Atty. Dkt. No.	M#	Client Ref.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Applicant: Andreas BERGMANN et al.		
				Appln. No.: unassigned		
				Filing Date: March 25, 2004		
Date: March 25, 2004		Page 3 of 4			Examiner:	Group Art Unit: unassigned

U.S. PATENT DOCUMENTS							
Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)	

FOREIGN PATENT DOCUMENTS						English Abstract	Translation Readily Available	
	Document Number	Date MM/YYYY	Country	Inventor Name				

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)		Enclosed	No	Enclose	No
	YARON, A., AND NAIDER , F. : "Proline-Dependent Structural and Biological Properties of Peptides and Proteins" CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 28, 1993, pages 31-81, XP000925565, page 55, column 1, line 15 – column 2, page 56, column 2, paragraph 2 – pa 57, column 1, line 3				
	ORAVECZ T ET AL : "REGULATION OF THE RECEPTOR SPECIFICITY AND FUNCTION OF THE CHEMOKINE RANTES (REGULATED ON ACTIVATION, NORMAL T CELL EXPRESSED AND SECRETED) BY DIPEPTIDYL PEPTIDASE IV (CD26)-MEDIATED CLEAVAGE" JOURNAL OF EXPERIMENTAL MEDICINE, JP, TOKYO, vol. 186, no. 11, 1 December 1997, pages 1865-1872, XP002056059 ISSN: 0022-1007 cited in the application, the whole document				
	P PROOST ET AL : "Amino-terminal truncation of chemokines by CD26/Dipeptidyl-peptidase IV" JOURNAL OF BIOLOGICAL CHEMISTRY, US, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 273, no. 13, 27 March 1998, pages 7222-7227-7227, XP002102982 ISSN: 0021-9258 cited in the application, the whole document				
	WRENGER, S. ET AL : " Amino-terminal truncation of procalcitonin, a marker for systemic bacterial infections, by dipeptidyl peptidase IV (DP IV)." FEBS LETTERS, (JAN. 21, 2000) vol. 466, No. 1, pp. 155-159., XP002143500, the whole document				
	Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis, Eric S. Nylen et al, Crit Care Med. 1998, vol. 26, No. 6, pages 1001 – 1006				
	Biochemistry 1998, 37, pages 12672 – 12680 " FunctionalComparison of Two Human Monocyte Chemotactic Protein-2 Isoforms, Role of the Amino-Terminal Pyroglutamic Acid and Processing by CD26/Dipeptidyl Peptidase IV" Els Van Coillie et al, 1998 American Chemical Society, Published on Web 08/18/1998				

Examiner	Date Considered:
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449 (modified) To: U.S. Department of Commerce (PW FORM PAT-1449) Patent and Trademark Office		Atty. Dkt. No.	M#	Client Ref.
			0308769	

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Date: March 25, 2004

Page **4** of **4**

Applicant: Andreas BERGMANN et al.

Appln. No.: unassigned

Filing Date: March 25, 2004

Examiner: Group Art Unit: unassigned

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)

FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

	PROW and IWHLDA present the GUIDE on : DC 26 Author : Martin Hegen, Reviewer: Tamas Oraveez 4 pages		
	PRO-GASTRIN-RELEASING PEPTIDE (ProGRP) – A NEW MARKER IN SMALL-CELL LUNG CARCINOMAS, Petra Stieber et al, J Lab Med 1997, 21 (6) 336-344, pages 336 – 344		
	In vitro test for determination of Pro-Gastrin-Releasing Peptide (ProGRP) in serum by EIA, ProGRP ELISA KIT, 5 pages		

Examiner _____ Date Considered: _____

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.